Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Cardiac Monitoring for Patients Undergoing Treatment With MEK Inhibitor Monotherapy.
Journal: Current oncology reports
Published: May 05, 2026
Clinical Utility of [18F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma.
Journal: AJNR. American journal of neuroradiology
Published: October 08, 2025
Clinical Utility of [F18]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma.
Journal: AJNR. American journal of neuroradiology
Published: October 08, 2025
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 08, 2024
A pilot survey into the landscape of neuro-oncology care in the community.
Journal: The oncologist
Published: October 01, 2024
Comparison of dynamic susceptibility contrast (DSC) using gadolinium and iron-based contrast agents in high-grade glioma at high-field MRI.
Journal: The neuroradiology journal
Published: March 28, 2024
Deciphering spatially distinct immune microenvironments in glioblastoma using ferumoxytol and gadolinium-enhanced and FLAIR hyperintense MRI phenotypes.
Journal: Neuro-oncology advances
Published: December 11, 2023
Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Journal: Cold Spring Harbor molecular case studies
Published: February 14, 2023
Primary central nervous system lymphoma: advances in MRI and PET imaging.
Journal: Annals of lymphoma
Published: August 22, 2022
Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors.
Journal: Neuro-oncology advances
Published: July 27, 2022
[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
Journal: Neuro-oncology practice
Published: May 23, 2022
Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis.
Journal: Neuro-oncology advances
Published: April 07, 2022
Last Updated: 09/26/2026